Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (INR)98.85
  • Today's Change-0.10 / -0.10%
  • Shares traded269.63k
  • 1 Year change-57.99%
  • Beta1.8920
Data delayed at least 15 minutes, as of Nov 25 2022 10:15 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Dishman Carbogen Amcis Limited is engaged in contract research and manufacturing services (CRAMS) and the manufacture and supply of marketable molecules, such as specialty chemicals, vitamins and chemicals, and disinfectants. The Company's segments include CRAMS and Vitamin - D, Bulk Drugs, Quats, Specialty Chemicals and traded goods. The Company assists pharma companies through various stages of drug development from process research and development to late-stage clinical and commercial manufacturing facilities, along with the supply of active pharmaceutical ingredients (APIs) and intermediates. The Company has manufacturing and research facilities in India, Switzerland, France, Netherlands, United Kingdom and China. The Company's subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd., CARBOGEN AMCIS Holding AG and Dishman Biotech Ltd.

  • Revenue in INR (TTM)22.86bn
  • Net income in INR-152.40m
  • Incorporated2007
  • Employees1.17k
  • Location
    Dishman Carbogen Amcis LtdDishman Corporate HouseIscon-Bopal Road, AmbliAHMEDABAD 380058IndiaIND
  • Phone+91 2 717420102
  • Fax+91 7 926420198
  • Websitehttps://www.carbogen-amcis.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
NGL Fine-Chem Ltd2.96bn-781.07m10.25bn329.00--4.95--3.47-126.42-126.42478.66334.811.095.135.338,981,979.00-28.8817.96-38.1324.1815.8848.76-26.4314.831.94-53.650.13272.9323.0824.42-12.0327.3722.93--
Bajaj Healthcare Ltd7.16bn632.95m10.88bn1.05k17.203.0512.741.5222.9322.93259.42129.310.96653.123.876,808,470.008.5411.3815.7819.7025.7625.658.848.640.71665.780.4949--3.4924.14-14.1155.6150.96--
Medicamen Biotech Ltd1.22bn137.13m10.93bn357.0077.675.8854.798.9611.1211.1298.97146.870.52812.941.953,417,785.005.948.028.1611.9751.0833.6611.2410.621.776.780.13299.012.426.9622.8223.6229.990.00
TTK Health Care Ltd6.80bn226.35m12.68bn2.59k55.981.3735.181.8616.03448.38481.19656.990.77024.509.102,626,766.002.565.083.598.3750.9356.703.333.763.531.370.024834.3125.882.57-49.68-0.24633.7214.87
Suven Life Sciences Ltd.165.80m-939.96m14.05bn117.00--18.01--84.77-6.43-6.431.123.580.1810.0011.021,417,077.00-102.59-9.45-165.56-10.9278.6565.15-566.93-19.841.32-252.260.4792---12.12-53.49-69.08---8.33--
Morepen Laboratories Ltd14.70bn552.86m14.75bn2.38k26.552.0017.801.001.091.0928.8814.411.414.396.146,182,353.
RPG Life Sciences Limited4.83bn603.30m14.97bn1.17k24.815.3919.773.1036.4936.49292.16168.051.382.128.944,146,781.0017.2010.2822.8014.9566.6061.7012.497.691.71194.560.001527.4313.117.4928.7033.61-15.5827.94
Dishman Carbogen Amcis Ltd22.86bn-152.40m15.50bn1.17k--0.2795.200.6781-0.968-0.968146.44354.250.26330.79535.4219,568,840.00-0.17560.9727-0.21171.1776.8274.41-0.66683.820.71790.13050.2685103.4111.964.55110.91-34.1525.67--
Novartis India Ltd4.20bn537.10m16.27bn81.0030.292.2026.913.8821.7521.75169.92299.320.4264.459.0851,817,280.005.453.136.623.9751.9657.4212.807.183.4619.270.028975.564.86-9.43-117.80---29.150.00
Orchid Pharma Ltd6.36bn-356.44m16.34bn1.80k--2.6328.602.57-8.72-10.00155.37152.330.55761.734.86---2.55-4.56-3.26-9.1342.6650.02-4.58-18.160.8107-0.48430.3531--24.33-7.0736.56--10.67--
Hester Biosciences Ltd2.36bn271.17m16.51bn584.0062.576.2534.476.9931.0131.01266.54310.440.44780.92733.614,041,
Solara Active Pharma Sciences Ltd11.30bn-1.64bn16.96bn2.25k--1.13--1.50-45.74-45.74313.98416.260.38161.291.915,011,535.00-5.56---8.72--40.39---14.56--0.5475-1.870.3934---21.56---126.26------
Alembic Limited969.02m1.50bn18.69bn305.0012.500.773723.4319.295.835.833.7794.100.03760.38626.683,177,115.002.863.402.943.5268.6950.2176.2358.120.925742.910.00--6.39-11.87-35.238.8420.12--
Supriya Lifescience Ltd5.19bn1.28bn19.68bn--15.373.0214.163.7915.9115.9164.5381.000.81962.116.28--20.22--24.98--60.40--24.67--4.388.520.0529--37.54--22.60------
Amrutanjan Health Care Ltd3.99bn517.13m20.59bn647.0039.937.5636.535.1617.6717.67136.3093.391.177.1011.516,165,725.0015.2218.3019.6122.8253.4354.9712.9613.462.90151.070.002321.8321.9313.329.8023.7943.8933.13
Data as of Nov 25 2022. Currency figures normalised to Dishman Carbogen Amcis Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

8.77%Per cent of shares held by top holders
HolderShares% Held
HBM Partners AG (Investment Management)as of 30 Sep 20225.56m3.55%
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 30 Sep 20212.95m1.88%
L&T Investment Management Ltd.as of 31 Oct 20222.38m1.52%
ICICI Prudential Asset Management Co. Ltd.as of 31 Oct 20221.25m0.80%
Dimensional Fund Advisors LPas of 03 Nov 20221.22m0.78%
SSgA Funds Management, Inc.as of 03 Nov 2022187.51k0.12%
quant Money Managers Ltd.as of 31 Oct 2022132.55k0.09%
Dimensional Fund Advisors Ltd.as of 04 Nov 202251.87k0.03%
American Century Investment Management, Inc.as of 03 Nov 202222.10k0.01%
DFA Australia Ltd.as of 30 Sep 20224.02k0.00%
More ▼
Data from 30 Sep 2022 - 23 Nov 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.